跳至主要内容
临床试验/NL-OMON48426
NL-OMON48426已完成4 期

A 12-week randomized, controlled trial to compare TOUJEO® and TRESIBA® in terms of glucose values in target range and variability during continuous glucose monitoring in patients with type 1 diabetes mellitus - inRange

Sanofi-aventis0 个研究点目标入组 45 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Participants with Type 1 Diabetes mellitus (T1DM)
  • Participants treated with multiple daily injections (MDI) using basal insulin
  • analog once daily and rapid acting insulin analogs for at least one year
  • HbA1c * 7% (48 mmol/mol) and * 10% (86 mmol/mol) at screening

排除标准

  • Participants not on stable dose of basal insulin analog
  • Participants having received Toujeo or Tresiba as basal insulin within 30 days
  • prior to screening
  • Participants not using the same insulins (both basal and rapid) within 30 days
  • prior to screening
  • Participants having received basal insulin dose *0.6 U/kg body weight within 30
  • days prior to screening
  • Participants having received any glucose lowering drugs (including any premixed
  • insulins,human regular insulin as mealtime insulins, any others injectable or
  • oral), other than basal and rapid insulin analogs, within 3 months prior to
  • End stage renal disease or on renal replacement treatment
  • Retinopathy or maculopathy with one of the following treatments, either recent
  • (within 3 months prior to screening) or planned: intravitreal injections or
  • laser or vitrectomy surgery
  • Body weight change *5 kg within 3 months prior to screening

研究者

相似试验

A 12-week randomized, controlled trial to compare... | 临床试验